



AIUM/QIBA Ultrasound Volume Blood Flow Biomarker

CALL SUMMARY 4-May-2020

Action Items in RED.

Attendance:

Brian Fowlkes, Oliver Kripfgans, Mark Lockhart, Jin Gao, David Dubberstein, Cristel Baiu, Paul Carson, Matthew Bruce, Jon Rubin, Shiram Sethuraman, Ron Leichner,

- 1. Review of Previous Call Summary
 - 1.1. Reviewed with no changes.
- 2. Discussion regarding the revised Radiology manuscript for VF
 - 2.1. Oliver updated the group that we are waiting for final acceptance of the manuscript.
- 3. Profile and protocol discussion
 - 3.1. Subsections need to be worked on
 - 3.1.1. A doodle poll will be scheduled to strategize conquering sections
 - 3.2. Brian Fowlkes presented an overview on profile development (Slide deck

"ProfileOverview_04May2020"

- Clinical
 - o Determine conditions under which reproducibility is achieved
 - Determination of accuracy
- Review of test results using QIBA phantom
 - Establish accuracy of methods in controlled conditions (using phantoms sent to different institutions)
 - Three Systems Tested; Canon, GE Logiq LE9; Philips Epiq7
 - Gain dependence
 - Flow range dependence
 - Depth range dependence
 - Summary of phantom results (differences still being examined)
 - Accuracy: 11.5% mean bias
 - Reproducibility: 10.4% mean within-subject CV (wCV)
 - Mean bias is probably too high due to one system
 - o Performance improvements being investigated
- Two studies in umbilical venous flow
 - Pinters et al (JUM 2017)
 - Reproducibility : Intrapatient relative SD (CV) = 20.3+/-10.1% (wCV)

- o Rubin et al (Abstract for 2020 AIUM meeting and manuscript submitted)
 - Mean within-subject coefficient of variation (wCV)
 - Spectral Doppler method : 46 ± 17%
 - Gaussian surface method : 18 ± 14%
- Potential Profile Claims
 - Claim 1 (cross-sectional): For a measured volume blood flow of X mL/min, a 95% confidence interval for the true flow is $X \text{ mL/min } \pm 15\%$.
 - Claim 2 (technical performance claim): The volume flow measurement has a withinsubject coefficient of variation (wCV) < 20%.
- Discussion of Claims
 - We discussed how these as compare to those of the SWS Profile
 - Claim 1
 - Consider depth range over which the claims would apply
 - Consider velocity range over which the claims would apply
 - Consider is there are any distinction for constant vs. pulsatile flow
 - Tim Hall suggested that one might consider criteria based on PSF/vessel diameter
 - Claim 2
 - Any subclaims that might be application specific
 - Current claim seems aligned with experience with umbilical cord.
 - Consider other applications
 - Dialysis Grafts: Average COV 9.89 ± 8.02% based on 2D spectral Doppler – Based on analysis of UAB data
 - o Brian F. pointed out the QIBA Profile Claim Guidance document
- https://qibawiki.rsna.org/images/a/a1/QIBAProfileClaimGuidance-2017_02_17.pdf

QIBA Volume Flow Profile Info May 4, 2020

1

Clinical Objectives • Provide an accurate and reproducible measurement of volumetric blood flow Determine conditions under which reproducibility is achieved Standard scanning procedures Range of vessel sizes Range of depths · Determination of accuracy Identify possible conditions where reference standard exist



Testing To Be Published

Three systems

- Canon Aplio 500 (Canon Medical Systems Inc., Tustin, CA) with a mechanically swept 9CV2 probe
- GE LOGIQ LE9 (GE Healthcare, Milwaukee, WI) with a mechanically swept RSP6-16 probe
- Philips EPIQ 7 (Philips Healthcare, Bothell, WA) with an X6-1 2D matrix array

4

2









Summary of Phantom Results

- Volume flow estimated by 3D color flow ultrasound was Accurate (11.5% mean bias) Reproducible (10.4% mean within-subject COV)
- There were differences among systems that are still being examined. • There are changes being made to systems expecting to improve performance.

Testing Objectives Achieved

- Two studies in human umbilical venous flow • Pinter et al. (JUM 2017)
 - Rubin et al. (Abstract for 2020 AIUM meeting and manuscript submitted)

9

10

Pinter et al.

- 35-patient cohort could be classified into 3 groups

 - 21 at-risk patients 5 patients with preeclampsia
 - 9 patients with normal pregnancies
- LOGIQ E9 ultrasound system (GE Healthcare, Milwaukee, WI)
 - 2.0-8.0-MHz bandwidth convex array transducer (RAB6-D)
 - Mechanically- swept array
 30 volumes per data set
 - 5-10 minute acquisition time

Pinter et al.

- Free cord loop imaged
- · Generally 3 different free loop positions along the length of the umbilical cord
- 5 patient had only two positions
 1 patient had only one position
- Imaging depth range
- 3.3-11.0 cm





13

15



• Free cord loop imaged



16

14

Study Results

Rubin et al.

High risk gestations

2D array transducer
X6-1 or XL14-3 Body habitus
Depth range
Availability

Hospitalized during pregnancy

24 to 35 5/7 weeks
 Singleton
 Philips EPIQ 7 ultrasound scanner

• 12 subjects

Gestation

• The true flow was unknown for these case (no reference standard)

- Mean within-subject coefficient of variation (wCV)
 - Spectral Doppler method : 46 ± 17%
 Gaussian surface method : 18 ± 14%

Potential Associated Claims

- Claim 1: (cross-sectional) For a measured volume blood flow of X mL/min , a 95% confidence interval for the true flow is X mL/min ±15%.
- Claim 2 : (technical performance claim) The volume flow measurement has a within-subject coefficient of variation (wCV) < 20%.

17

Thoughts on Claim 1

- If we look at the results of the QIBA phantom study there can be additional restrictions considered.
- Depth range over which a given accuracy can be achieved.
- 2) Velocity range over which it has been tested.
 3) Any difference in such specifications between
- 3) Any difference in such specifications between pulsatile and constant flow.
- Need to define the range over which we will intend for the profile to apply.
 What is the rationale?
- What can be stated from work done so far (QIBA round robin study, etc.)
- Reconsider in favor of defining a PSF/vessel diameter criteria

19

Thoughts on Claim 2

- Add any application specific claim(s) (absolute or longitudinal).
- The term "technical performance claim" appears appropriate for a similar type of claim.
- This is based on the performance in umbilical venous flow.
 Consider other sources such as dialysis grafts
 Average COV 9.89 ± 8.02% based on 2D spectral Doppler

20

Overall Considerations

- What is needed for the clinical purpose?
 Accuracy
 - Reproducibility
- Claims construction process



21

22